Showing 3351-3360 of 5621 results for "".
- Optos Launches Silverstone RGB Retinal Imaging Technologyhttps://modernod.com/news/optos-launches-silverstone-rgb-retinal-imaging-technology/2484187/Optos announced the launch of Silverstone RGB. Building on its flagship Silverstone platform, the new system is designed to deliver a suite of nine imaging modalities in a single device, establishing a new benchmark in retinal imaging technology.
- EssilorLuxottica Acquires RetinAI, Maker of AI and Data Management Technologyhttps://modernod.com/news/essilorluxottica-acquires-retinai-maker-of-ai-and-data-management-technology/2484183/EssilorLuxottica announced it is acquiring Ikerian AG, a Swiss health technology company operating under the RetinAI brand. Financial terms of the deal were not disclosed.
- Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatmenthttps://modernod.com/news/avisi-technologies-receives-fda-approval-to-study-novel-approach-to-glaucoma-treatment/2484182/Avisi Technologies announced that the FDA has approved an investigational device exemption (IDE) for its glaucoma treatment device, VisiPlate. This milestone paves the way for the company’s SAPPHIRE clinical trial, which will evaluate the device in patie
- Iantrek Announces US Commercial Launch of AlloFlo Uveo, First Surgical Treatment Targeting the Uveoscleral Pathwayhttps://modernod.com/news/iantrek-announces-us-commercial-launch-of-alloflo-uveo-first-surgical-treatment-targeting-the-uveoscleral-pathway/2484180/Iantrek announced the official US commercial launch of AlloFlo Uveo, the first surgical treatment specifically designed to target the uveoscleral pathway. This milestone follows Iantrek’s $42 million Se
- SpyGlass Pharma Announces Promising 24-Month Interim Results from First-in-Human Trial of BIM-IOL Systemhttps://modernod.com/news/spyglass-pharma-announces-promising-24-month-interim-results-from-first-in-human-trial-of-bim-iol-system/2484179/SpyGlass Pharma announced interim 24-month data from its first-in-human clinical trial evaluating the Bimatoprost Drug Pad-IOL System (BIM-IOL System). This technology integrates proprietary non-bioerodible drug pads with SpyGlass Pharma’s IOL, designed
- PulseSight: New Peer-Reviewed Data Highlighting Transferrin’s Therapeutic Potential for Dry AMDhttps://modernod.com/news/pulsesight-new-peer-reviewed-data-highlighting-transferrins-therapeutic-potential-for-dry-amd/2484176/PulseSight Therapeutics welcomed the publication of new scientific data reinforcing the therapeutic promise of transferrin (Tf) for the treatment of dry age-related macular degeneration (AMD). The study, conducted by
- BVI Receives FDA Approval for Finevision HP Trifocal IOLhttps://modernod.com/news/bvi-receives-fda-approval-for-finevision-hp-trifocal-iol/2484174/BVI announced that the FDA has approved its Finevision HP trifocal IOL. According to BVI, Finevision HP was the world’s first trifocal IOL, with more than 15 years of clinical success a
- Rayner Secures FDA Approval for RayOne EMV Toric IOLhttps://modernod.com/news/rayner-secures-fda-approval-for-rayone-emv-toric-iol/2484172/The FDA has approved Rayner's RayOne EMV Toric IOL following the completion of a pivotal investigational device exemption (IDE) study. According to Rayner, the RayOne EMV Toric lens has been enginee
- Celltrion Receives FDA Approval for Eylea Biosimilar Eydenzelthttps://modernod.com/news/celltrion-receives-fda-approval-for-eylea-biosimilar-eydenzelt/2484171/The FDA has approved Celltrion's Eydenzelt (aflibercept-boav), a biosimilar referencing Eylea (aflibercept), for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO)
- Konan Medical Receives CE Marking for ObjectiveFIELD Analyzer (OFA)https://modernod.com/news/konan-medical-receives-ce-marking-for-objectivefield-analyzer-ofa/2484170/Konan Medical USA announced that its objectiveFIELD Analyzer (OFA) has received CE Marking under the European Medical Device Regulation (MDR). The CE Mark enables Konan Medical to offer its next-generation perimetry solution to healthcare providers throug